The sale of assets to the Institute for Environmental Health comes after an extensive review of strategic alternatives for Roka, the company said.
The announcement comes three weeks after Interleukin said it was laying off 63 percent of its workforce and suspending sales of a controversial genetic test.
After selling Focus Diagnostics' products business to DiaSorin for $300 million, Quest now estimates annual revenues of between $7.47 billion and $7.54 billion.
The company said selling this business unit frees it to focus on developing new maternal and fetal health solutions for the US and elsewhere.
Hologic will purchase the assets via its subsidiary Gen-Probe, from which DiagnoCure will repurchase Series A shares worth C$1 million.
Tute will offer interpretation and annotation software from Knome's KnoSys appliance as part of its existing cloud offering but is open to providing a local option for interested clients.
Adstec will assume the business, financial, and human resource commitments of the business and pay Transgenomic $300,000 for stock and inventory related to the business.
True Health made its bid last week in an auction, increasing it from an original $32 million in order to beat out other potential buyers.
An undisclosed buyer has offered between $115 million and $125 million for the POC business and Chinese firm Jinjing Group has officially expressed interest.
If the non-binding proposal falls through, the German firm plans to spin off its molecular diagnostics business into a separate entity.
The New York Times profiles 23andMe's Anne Wojcicki and describes how she bounced back from a bad year.
Fotis Kafatos, the founding president of the European Research Council, has died, according to the Associated Press.
In PLOS this week: genomic analysis of honeybee disease, microRNA profiles of people with lupus nephritis, and more.
The Verge's Angela Chen tried out a gene test for fitness advice, but didn't learn much new information.